海通证券股份有限公司关于沈阳兴齐眼药股份有限公司 3 | 3.与同行业可比公司比较，公司业绩是否不存在明显异常 | √ | | | --- | --- | --- | | （七）公司及股东承诺履行情况 | | | | 现场检查手段： | | | | （一）对上市公司相关负责人员进行访谈； | | | | （二）查阅公司及股东相关承诺及其履行情况的相关文件、信息披露等资料。 | | | | 1.公司是否完全履行了相关承诺 | √ | | | 2.公司股东是否完全履行了相关承诺 | √ | | | （八）其他重要事项 | | | | 现场检查手段： | | | | （一）对上市公司相关负责人员进行访谈； | | | | （二）查阅并核查公司现金分红制度及其执行情况； | | | | （三）查阅公司关于对外提供财务资助、重大投资、重大合同、大额资金往来等其他 | | | | 重要事项的相关合同、凭证、三会文件、信息披露文件等资料； | | | | （四）查阅行业发展状况等资料，网络搜索相关媒体报道。 | | | | 1.是否完全执行了现金分红制度，并如实披露 | √ | | | 2.对外提供财务资助是否合法合规，并 ...

证券代码：300573 证券简称：兴齐眼药 公告编号：2024-022 沈阳兴齐眼药股份有限公司 关于调整部分募投项目投资总额、内部投资结构 及实施进度的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 沈阳兴齐眼药股份有限公司（以下简称"公司"）于 2024 年 4 月 17 日召开 第五届董事会第二次会议、第五届监事会第二次会议，审议通过了《关于调整部 分募投项目投资总额、内部投资结构及实施进度的议案》，同意公司以自有资金 增加部分募投项目的投资总额并调整内部投资结构，同时调整部分募投项目的实 施进度。本次事项尚需提交股东大会审议，现将有关情况公告如下： 一、募集资金投资项目概述 经中国证券监督管理委员会《关于同意沈阳兴齐眼药股份有限公司向特定对 象发行股票注册的批复》（证监许可[2021]1343 号）核准，并经深圳证券交易所 同意，公司向特定对象发行人民币普通股 5,763,282 股，募集资金总额为人民币 599,669,492.10 元 ， 扣 除 各 项 发 行 费 用 后 ， 募 集 资 金 净 额 为 人 民 币 580,179,086. ...

证券代码：300573 证券简称：兴齐眼药 公告编号：2024-015 沈阳兴齐眼药股份有限公司 第五届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、本次董事会由董事长刘继东先生召集，会议通知于 2024 年 4 月 7 日通过 电子邮件的形式送达至全体董事，董事会会议通知中包括会议的相关资料，同时 列明了会议的召开时间、地点、内容和方式。 2、本次董事会于 2024 年 4 月 17 日在公司会议室以现场会议的方式召开。 3、本次董事会应到 9 人，实际出席会议人数为 9 人。 4、本次董事会由董事长刘继东先生主持，公司监事和高级管理人员列席了 本次董事会。 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法 律法规和《公司章程》的有关规定。 二、董事会会议审议情况 会议审议并通过了如下议案： （三）审议通过《关于<2023 年度财务决算报告>的议案》 同意《关于<2023 年度财务决算报告>的议案》。董事会认为，公司 2023 年 度财务决算报告客观、真实地反应了公司 2023 年度的 ...

（本页无正文，为《沈阳兴齐眼药股份有限公司监事会关于 2023 年度内部控制 的自我评价报告审核意见》签字页） 沈阳兴齐眼药股份有限公司监事会关于 2023 年度内部控制的自我评价报告审核意见 根据《中华人民共和国公司法》《深圳证券交易所创业板股票上市规则》《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《企 业内部控制基本规范》等相关法律法规和沈阳兴齐眼药股份有限公司（以下简称 "公司"）的公司章程、《监事会议事规则》等公司制度的有关规定，公司监事会 审阅了公司《2023 年度内部控制的自我评价报告》后，发表如下意见： 监事会认为，公司已建立了较为完善的内部控制制度体系，能够适应公司管 理的要求和公司发展的需要，为编制真实、公允的财务报表提供合理的保证，并 能得到有效的执行。报告期内公司的内部控制体系规范、合法、 有效，没有发 生违反公司内部控制制度的情形。公司《2023 年度内部控制的自我评价报告》真 实、客观地反映了公司内部控制制度的建设及运行情况。 （以下无正文） ———————— ———————— ———————— 监事签名： 曲晓禹 戢飞 李冰 ...

证券代码：300573 证券简称：兴齐眼药 公告编号：2024-023 沈阳兴齐眼药股份有限公司 关于向银行申请授信的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 沈阳兴齐眼药股份有限公司（以下简称"公司"）于 2024 年 4 月 17 日召开 第五届董事会第二次会议，审议通过了《关于向银行申请授信的议案》，现将相 关情况公告如下： 根据正常业务的资金需求，公司拟向中国工商银行沈阳经济技术开发区支行 申请 10,000 万元人民币授信额度。 以上授信额度不等于公司的实际融资金额，实际融资金额应在授信额度内以 银行与公司实际发生的融资金额为准。 授权公司董事长及其授权人士代表公司全权办理该授信事宜，包括但不限于 代表公司签订以及根据公司情况修改相关文件、合同，由此产生的法律、经济责 任全部由公司承担。 本次申请银行授信额度无需提交公司股东大会审议。 特此公告。 沈阳兴齐眼药股份有限公司 董事会 2024 年 4 月 19 日 ...

Financial Performance - The company reported a total revenue of CNY 1.2 billion for the year 2023, representing a year-on-year growth of 15%[16]. - The company's operating revenue for 2023 was CNY 1,467,569,910.64, representing a 17.42% increase compared to CNY 1,249,855,370.83 in 2022[22]. - The net profit for 2023 was CNY 300 million, reflecting a growth of 12% from the previous year[16]. - The net profit attributable to shareholders for 2023 was CNY 240,036,047.12, reflecting a 13.39% increase from CNY 211,684,305.31 in 2022[22]. - The gross profit margin for the year was 60%, which is a slight improvement from 58% in 2022[16]. - The company aims to achieve a revenue target of CNY 1.5 billion for 2024, indicating a growth forecast of 25%[16]. - The total cash dividend amount represents 100% of the profit distribution for the year, indicating a strong commitment to returning value to shareholders[132]. Research and Development - The company will focus on improving its research and development capabilities and expanding its product pipeline to address the risks associated with new drug development and rising R&D costs[7]. - Research and development expenses increased by 25% to CNY 150 million, focusing on innovative drug formulations[16]. - The company has a strong R&D capability, recognized as a high-tech enterprise, and has been awarded 49 invention patents, enhancing its technological leadership in the ophthalmic pharmaceutical sector[51][52]. - The company’s R&D center has developed seven technical platforms for ophthalmic drug research, demonstrating its commitment to innovation and quality in drug development[51]. - The company plans to develop new drugs targeting various eye diseases, which is expected to enhance its market competitiveness[66]. Market Strategy and Expansion - The company aims to increase its market share and sales coverage to mitigate risks associated with potential performance slowdowns and unmet expectations due to intensified market competition[6]. - The company is expanding its market presence in Southeast Asia, targeting a revenue contribution of 10% from this region by 2025[16]. - The company recognizes the increasing competition in the pharmaceutical industry and intends to broaden its ophthalmic product line and explore new markets to sustain growth[5]. - The company is focused on enhancing its academic promotion efforts and market expansion to increase the number of hospitals and product sales[4]. - The company aims to leverage its R&D strengths and patent portfolio to enhance its competitive edge in the ophthalmic market[52]. Corporate Governance - The company has established a strict internal control management system covering key areas such as decision-making, asset management, and financial reporting, which was effectively implemented in 2023[98]. - The board of directors consists of 9 members, including 3 independent directors, and operates under various specialized committees to ensure compliance and effective governance[97]. - The company has an independent financial department with a standardized financial management system, ensuring independent financial decision-making and compliance with tax obligations[101]. - The company is committed to improving corporate governance and internal control systems to enhance transparency and investor protection[95]. - The company held 3 shareholder meetings during the reporting period, all convened by the board of directors, ensuring equal treatment of all shareholders through a combination of on-site and online voting[96]. Environmental Responsibility - The company has implemented various environmental protection measures in compliance with national and local regulations[147]. - The company reported a total wastewater discharge of 2.33 tons of COD, which is within the approved limit of 18.3978 tons[150]. - The ammonia nitrogen discharge was recorded at 0.2 tons, significantly below the approved limit of 1.83978 tons[150]. - The company has established an emergency response plan for environmental incidents, which has been registered in the national environmental emergency plan electronic filing system[152]. - The company has invested 3.84 million yuan in environmental protection efforts[156]. Employee Engagement and Development - The company has established a comprehensive training system to enhance employee competitiveness and support organizational development[128]. - The company maintains a competitive salary structure, focusing on attracting and retaining high-potential talent, with regular salary adjustments based on industry surveys[127]. - The total number of employees at the end of the reporting period was 1,995, including 1,558 at the parent company and 221 at major subsidiaries[125]. - The company has implemented a stock incentive plan to motivate and retain key employees, with the plan approved by the board and shareholders in 2021[134]. - The company has a clear profit distribution policy that ensures the protection of minority shareholders' rights[131]. Shareholder Information - The company proposed a cash dividend of 30.00 CNY per 10 shares (including tax), totaling 373,767,582.00 CNY for the 2023 fiscal year, subject to shareholder approval[130]. - The total number of shares held by the company's directors and supervisors is 38,510,252 shares[108]. - The company’s total share capital increased from 88,555,082 shares to 123,977,114 shares following a capital reserve distribution of 4 shares for every 10 shares held[183]. - Liu Jidong, a major shareholder, holds 28.60% of the shares, totaling 35,637,700 shares, with an increase of 10,322,200 shares during the reporting period[184]. - The company has not reported any changes in the top ten shareholders compared to the previous period[188]. Strategic Partnerships and Collaborations - The company has entered into a strategic partnership with a leading biotech firm to enhance its product pipeline and accelerate development timelines[16]. - The company emphasizes a collaborative R&D model, partnering with various research institutions and universities to boost innovation[53]. - The company is actively pursuing regulatory approvals for several new products, with multiple applications pending review by national authorities[49]. - The company continues to strengthen its marketing channels through partnerships with major e-commerce platforms like JD and Alibaba, achieving integrated growth across multiple sales channels[43]. - The company is actively involved in community and industry initiatives, enhancing its reputation and stakeholder engagement[112].

海通证券股份有限公司关于沈阳兴齐眼药股份有限公司 | （3）现场检查发现的主要问题及整改情况 | 无 | | | | --- | --- | --- | --- | | 6、发表专项意见情况 | | | | | （1）发表专项意见次数 | 4 次 | | | | （2）发表非同意意见所涉问题及结论意见 | 无 | | | | 7、向本所报告情况（现场检查报告除外） | | | | | （1）向本所报告的次数 | 0 次 | | | | （2）报告事项的主要内容 | 不适用 | | | | （3）报告事项的进展或者整改情况 | 不适用 | | | | 8、关注职责的履行情况 | | | | | （1）是否存在需要关注的事项 | 无 | | | | （2）关注事项的主要内容 | 不适用 | | | | （3）关注事项的进展或者整改情况 | 不适用 | | | | 9、保荐业务工作底稿记录、保管是否合规 | 是 | | | | 10、对上市公司培训情况 | | | | | （1）培训次数 | 1 次 | | | | （2）培训日期 | 年 2023 12 | 月 27 | 日 | | （3）培训的主要内容 | 创业 ...

本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：300573 证券简称：兴齐眼药 公告编号：2024-011 沈阳兴齐眼药股份有限公司 关于全资子公司完成工商变更登记的公告 沈阳兴齐眼药股份有限公司 沈阳兴齐眼药股份有限公司（以下简称"公司"）全资子公司沈阳兴齐眼科 医院有限公司（以下简称"兴齐眼科医院"）因业务发展需要对其经营范围进行 变更，并于近日完成了工商变更登记及备案手续，取得由沈阳市和平区市场监督 管理局颁发的《营业执照》，具体信息如下： 董事会 1、统一社会信用代码：91210100MA0UDW6Y9Y 2、名称：沈阳兴齐眼科医院有限公司 3、类型：有限责任公司（法人独资） 4、法定代表人：黎春华 5、经营范围：许可项目：医疗服务；药品零售；药品互联网信息服务；第 三类医疗器械经营；医疗器械互联网信息服务。（依法须经批准的项目，经相关 部门批准后方可开展经营活动，具体经营项目以相关部门批准文件或许可证件为 准）一般项目：第一类医疗器械销售；第二类医疗器械销售；眼镜销售（不含隐 形眼镜）；保健食品（预包装）销售；食品销售（仅销售预包装食品） ...

证券研究报告 | 公司点评 2024年 03月25日 兴齐眼药（300573.SZ） 低阿获批业绩或迎爆发，公司持续推动“质量回报双提升” 事件：公司发布《推动“质量回报双提升”行动方案》的公告，主要措施为： 买入（维持） （1）坚守初心，聚焦主业；（2）坚持研发创新，巩固竞争优势；（3）完善公 股票信息 司治理、提高规范运作水平；（4）坚持以投资者为本，与投资者共享发展成果； （5）践行ESG理念，实现高质量可持续发展。 行业 化学制药 前次评级 买入 点评：公司基本面优质，成长爆发性强。青少年近视防控成为新蓝海，低浓度 3月22日收盘价(元) 226.60 硫酸阿托品获批上市，1-2年内预计没有其他竞品上市，公司业绩或将迎来新 总市值(百万元) 28,231.91 增长，随着渗透率逐渐提升，未来增长潜力巨大。 总股本(百万股) 124.59 国内眼科药物龙头，低阿获批业绩或迎爆发。公司专注眼科药物研发生产， 其中自由流通股(%) 76.94 产品覆盖眼用抗菌、干眼治疗药等十余个眼科药物细分类别。公司营收增长 30日日均成交量(百万股) 3.68 稳健，近三年（2020年-2022年）营业收入复合增长率为 ...

Investment Rating - The report maintains a "Buy - A" investment rating for the company, with a target price of 214.50 CNY over the next six months [4][3]. Core Insights - The approval of low-concentration atropine eye drops is expected to lead to rapid sales growth, driven by a significant market opportunity due to the high prevalence of myopia among children aged 6 to 12 years, which reached 53.6% in 2022 [2][3]. - The competitive landscape is favorable as there are currently no similar products available in the domestic market for this indication, enhancing the potential for quick sales ramp-up [2]. - The company possesses strong academic promotion capabilities in the ophthalmology field, participating in numerous academic conferences and activities, which supports the effective marketing of low-concentration atropine [2]. Financial Projections - The revised profit forecast estimates the company's net profit attributable to shareholders for 2023, 2024, and 2025 to be 260 million CNY, 535 million CNY, and 614 million CNY, respectively, reflecting year-on-year growth rates of 22.9%, 105.6%, and 14.8% [3][8]. - The expected earnings per share (EPS) for 2024 is projected to be 4.29 CNY, with a price-to-earnings (PE) ratio of 50 times applied to derive the target price [3][8]. - The company's revenue is anticipated to grow significantly, with projected revenues of 1.46 billion CNY in 2023, 2.80 billion CNY in 2024, and 3.32 billion CNY in 2025 [8][9]. Market Performance - As of March 13, 2024, the company's stock price was 196.37 CNY, with a market capitalization of approximately 23.27 billion CNY [4]. - The stock has shown a relative performance of 10.5% over the past month and 36.2% over the past year [6].